A Study of Opevesostat (MK-5684) in China Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (MK-5684-001)

NCT06136598 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

14

Enrollment

INDUSTRY

Sponsor class

Conditions

Prostatic Neoplasms
Metastatic Castration-Resistant Prostate Cancer

Interventions

DRUG: Opevesostat
DRUG: Dexamethasone
DRUG: Fludrocortisone
DRUG: Hydrocortisone

Sponsor

Merck Sharp & Dohme LLC

Collaborators

[object Object]